United StatesPharmaceutical companies are attempting to persuade U.S. policymakers to reconsider proposed restrictions on investments in Chinese firms. These efforts come amid growing concerns over national security and intellectual property risks associated with Chinese biotechnology and pharmaceutical sectors. Industry leaders argue that overly broad restrictions could hinder innovation and collaboration, potentially harming both American and global patients. The issue has gained attention as several major drugmakers seek to maintain access to Chinese research and manufacturing capabilities. While some lawmakers support stricter oversight, others emphasize the importance of maintaining open channels for scientific advancement.
Bias read (Center): The article presents the situation neutrally, highlighting the positions of pharmaceutical companies seeking to influence policy while noting the broader debate among lawmakers. There is no overtly biased language, and the framing remains balanced between industry concerns and potential regulatory考量
